Change in LLVA from baseline at 1 year (ETDRS letters) · adults with GA due to AMD
1 finding from 1 review
QoL · adults with GA due to AMD
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Safety: Development of macular neovascularisation or exudative AMD at 1 year · adults with GA due to AMD
Summary of findings 1: Efficacy and safety of IVT lampalizumab… showed no clear difference in safety: Development of macular neovascularisation or exudative AMD… compared with sham (low certainty).
1 finding from 1 review
Safety: Development of endophthalmitis at 1 year · adults with GA due to AMD
Summary of findings 1: Efficacy and safety of IVT lampalizumab… showed no clear difference in safety: Development of endophthalmitis at 1 year compared with sham (moderate certainty).
1 finding from 1 review
Loss of ≥ 15 letters BCVA at 1 year · adults with GA due to AMD
Summary of findings 1: Efficacy and safety of IVT lampalizumab… showed no clear difference in loss of ≥ 15 letters BCVA at 1 year compared with sham (moderate certainty).
1 finding from 1 review
Change in LLVA from baseline at 1 year (ETDRS letters) · adults with GA due to AMD
1 finding from 1 review
QoL · adults with GA due to AMD
1 finding from 1 review
Change in visual acuity (logMAR) ‐ 12 months (negative is better) · adults with GA due to AMD
1 finding from 1 review
Change in untransformed GA lesion size from baseline at 1 year (mm²) · adults with GA due to AMD
1 finding from 1 review
Pain · acute non‐specific LBP
It is very uncertain whether exercise therapy changes pain compared with sham/placebo treatment (very low certainty).
1 finding from 1 review
Functional ability · acute non‐specific LBP
It is very uncertain whether exercise therapy changes functional status compared with sham/placebo treatment (very low certainty).
1 finding from 1 review
Perceived recovery · acute non‐specific LBP
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events · acute non‐specific LBP
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Pain · acute non‐specific LBP
1 finding from 1 review
Back‐specific functional status · acute non‐specific LBP
1 finding from 1 review
Perceived recovery · acute non‐specific LBP
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events · acute non‐specific LBP
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause mortality · otherwise healthy children aged 6 months to 12 years of age
Zinc supplementation showed no clear difference in all‐cause mortality compared with no zinc supplementation (high certainty).
1 finding from 1 review
Mortality due to all‐cause diarrhea · otherwise healthy children aged 6 months to 12 years of age
Zinc supplementation showed no clear difference in mortality due to all‐cause diarrhea compared with no zinc supplementation (moderate certainty).
1 finding from 1 review
Mortality due to LRTI · otherwise healthy children aged 6 months to 12 years of age
Zinc supplementation showed no clear difference in mortality due to LRTI compared with no zinc supplementation (moderate certainty).
1 finding from 1 review